Bayer’s Pipeline Push Meets a Chart That Won’t Budge
04.06.2026 - 17:53:29 | boerse-global.de
Bayer has just secured accelerated review status from the US Food and Drug Administration for three drug candidates, yet its stock remains locked in a technical struggle that is drawing far more attention than the pharma division’s recent wins. The divergence between operational progress and market sentiment is becoming increasingly stark.
Asundexian, a factor XIa inhibitor aiming to prevent stroke, and Kerendia, already approved for chronic kidney disease, both received the FDA’s fast-track designation. So did Sevabertinib, which targets a specific form of lung cancer. The moves signal tangible pipeline momentum, and Bayer has reinforced its ophthalmology ambitions by acquiring Perfuse Therapeutics. Meanwhile, the management team has installed Judith Hartmann as chief financial officer, effective 1 June 2026, sending a clear message of capital discipline.
Investors, however, remain fixated on the share price chart. The stock closed the most recent session at €35.42, a 2.61% gain on the day, but that bounce does little to mask the broader slide. Over seven days the equity has shed 6.37%, over 30 days it is down 6.40%, and since the start of the year the loss stands at 6.85%. The RSI reading of 39.2 confirms that selling pressure dominates, though the stock has not yet entered oversold territory.
Should investors sell immediately? Or is it worth buying Bayer?
All eyes are now on the 200-day moving average at €35.76. With the current price barely a percentage point below that threshold, a decisive move above it would provide short-term relief. Failure to reclaim it could trigger another leg lower. The 50-day line at €38.43 and the 100-day at €40.58 appear distant hurdles, and the 52-week high of €49.93 from February is now 29% away. Downside support lies at the 52-week trough of €25.09, though that is still 40% below the current level.
Looking back 12 months, Bayer’s stock has actually gained roughly 40%, making the recent weakness a correction within a longer uptrend. But the persistent legal overhang from Roundup glyphosate litigation continues to cap valuations, forcing every positive operational development to carry a discount. The annualised 30-day volatility of 38% underscores the unease.
If the chart can hold the technical floor around €34, the current zone may offer an attractive entry point. The combination of a new CFO, accelerated regulatory reviews and a solid crop-science business provides genuine fundamental ballast. For now, though, the short-term narrative will be dictated by whether traders can push Bayer back above that 200-day average.
Ad
Bayer Stock: New Analysis - 4 June
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
